DehydraTECH for Antivirals
Viral Infections
Pre-clinicalActive (Research)
Key Facts
About Lexaria Bioscience
Lexaria Bioscience is a pre-revenue, public biotech company commercializing its DehydraTECH™ drug delivery platform. Its core technology aims to improve the oral delivery of fat-soluble compounds, with demonstrated applications in cannabinoids and pharmaceuticals for conditions like hypertension and diabetes. The company's strategy relies on out-licensing its patented platform to generate future royalty and fee-based revenue, avoiding the high costs of drug development and commercialization. With a low market valuation and trading near its 52-week low, Lexaria represents a high-risk, high-potential investment in drug delivery innovation.
View full company profileOther Viral Infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |
| Cell-based Antiviral Drug Discovery Platform | Lucerna | Development |
| XAV19 | Xenothera | Preclinical |
| Antiviral Screening Services | NeoVirTech | Pre-clinical |
| Anti-Viral Program | MicroQuin | Pre-clinical |
| Satiasolv | Marinomed Biotech | Pre-clinical |